Stephen Anthony, DO

Trials

Studies that name Stephen Anthony, DO as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 00:03 UTC. Open this list on ClinicalTrials.gov

• Ph2
  NCT03969420 · Study of Alvocidib in Patients With Relapsed/Refractory AML Following Treatment With Venetoclax Combination Therapy

  Sumitomo Pharma America, Inc. · terminated · Acute Myeloid Leukemia (AML) · study director
• Ph1/Ph2
  NCT03593915 · A Phase 1b/2 Study of Alvocidib Plus Decitabine or Azacitidine in Patients With MDS

  Sumitomo Pharma America, Inc. · terminated · Myelodysplastic Syndromes (MDS) · study director
• Ph1
  NCT03298984 · Ph I Study of Alvocidib and Cytarabine/Daunorubicin (7+3) in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML).

  Sumitomo Pharma America, Inc. · completed · Acute Myeloid Leukemia · study director
• Ph2
  NCT02520011 · Alvocidib Biomarker-driven Phase 2 AML Study

  Sumitomo Pharma America, Inc. · terminated · Acute Myeloid Leukemia · study director
• N/A
  NCT01919749 · A Pilot Study Utilizing Proteomic and Genomic Profiling for Patients With Metastatic Breast Cancer

  Translational Drug Development · completed · Metastatic Breast Cancer · principal investigator

Grants

NIH projects from RePORTER, fetched 2026-11-12 00:03 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 87 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.

No NIH project could be tied to this name by a shared trial or a matching institution.